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Agenda 
• Study Rationale 
• Study Sponsor and Research Team 
• Literature Review/Focus Group and 
Interview Findings 
• Pilot Study Design 
• Next Steps 
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The Issue of Childhood Cancer 
• Cancer is the number one cause of 
death by disease for children 
• Approximately 12,000 children were 
diagnosed in 2012 
• 5-year survival rate is 83% 
 
• Quality of life for the entire family 
remains a concern 
 
• Evidence-based interventions to help 
the family during this experience are 
needed 
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Why the Canines and Childhood Cancer (CCC) Study? 
• Animal-assisted therapy (AAT) is a 
promising intervention to help families 
dealing with childhood cancer 
 
• Studies regarding human-animal 
interactions date back to the late 1970’s 
• Primarily anecdotal  
• Lack scientific rigor 
 
• As a result, AAT has received:  
• Limited recognition by medical 
professionals 




CCC Study Features 
• Randomized control cohort 
• Multi-site 
• Large sample size 
• Validated measurement instruments 
www.americanhumane.org 
American Humane Association 
• The country’s first national humane 
organization 
 
• The only charity dedicated to the 
protection of both children and animals 
 
• Mission since 1877:  
• Ensure the welfare, wellness and well-
being of children and animals 
• Unleash the full potential of the bond 
between humans and animals to the 




• Formerly the animal health 
business of Pfizer 
• Working to ensure a safe, 
sustainable global food supply 
• Helping dogs, cats and horses 
live healthier and longer lives 
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CCC Study Plan 
Stage I  
• Comprehensive Literature Review and 
Focus Groups/Interviews 
• Pilot Study Design 
• Site Recruitment/IRB and IACUC 
Stage II  
• Conduct Pilot Study 
• Data Analyses & Report Generation 
Stage III  
 
• Finalize Full Trial Study Design 
 
• IRB/IACUC Full Trial Processes 
 
• Conduct Full Clinical Trial 
 
www.americanhumane.org 
Literature Review  
• Published in January 2012 
• Intended to serve as a study background and a resource to 
the pediatric oncology and human-animal interaction fields 
• Covers more than 150 literature sources 
• Reviewed by experts in pediatric medicine, animal welfare 
and behavior, and human-animal interaction 
• Available at: www.caninesandchildhoodcancer.org  
 
www.americanhumane.org 
Focus Group and Interview Process 
• Focus groups and interviews were conducted 
with three sites to inform study design and 
planning:  
 
• East Tennessee Children’s Hospital in    
Knoxville, TN 
• University of TN College of Veterinary 
Medicine 
 
• Monroe Carell Jr. Children’s Hospital at 
Vanderbilt in Nashville, TN 
 




Summary of Findings from Literature Review, 







Brief Overview of Pediatric Oncology 
• Over the past 2 decades, while the incidence of 
cancer has increased slightly, the mortality rates 
from cancer have drastically decreased 
 
• Leukemia is the most common form of all 
childhood cancers  
• Most prevalent in children under the age of 10 
years, peaked around age 3-4 years 
• Treatment is approximately 2 years for females 
and 3 years for males 








• Distress and anxiety  
• Anger 
• Body image, self-esteem, and identity issues 
• Depression 
• Academic performance 
• Fear of infection, relapse, or death 
• Immunosuppression 
• Mood and behavior swings due to steroids 
• Pain and discomfort 
• Social isolation  
• Worry about family wellbeing  





Effects of Childhood Cancer on Families 
• Distress and anxiety 
• Depression and grief 
• Fear of infection, relapse, and death 
• Guilt 
• Post traumatic stress symptoms 
• Financial and employment concerns 
• Social isolation and loneliness 
• Strain on relationships 
• Hard on siblings 
• Increased family closeness 








• Reduced stress and anxiety 
• Distraction from pain and worry 
• Decreased heart rate and blood 
pressure 
• Help with coping 
• Mood elevation  
• Decrease loneliness 
• Facilitate rapport and social 
interaction between people 
• Normalize the hospital experience 




Safely Implementing AAT in Hospitals 
• Human safety and well-being 
• Risk management and infection control policies 
and procedures 
 
• Therapy dog safety and well-being   
 
• Animal-handler team training and 
certification 
 
• Setting and participant selection 
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• Handlers and their dogs visit from room 
to room and in common areas 
• Interact with both patients and families 
• Handlers and dogs typically visit once a 
week 
• Length of time with each child and family 
varies 
• Handler’s role is to advocate for their dog 
• Typical conversation is around the dog’s 
characteristics and about the family’s pets 
• Activities may include petting, brushing, 
and giving the dog commands 
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Current State of AAT Research   
• Rigorous and evidence-based research in the field of AAT continues to be lacking  
 
• Much of our understanding of AAT effectiveness is based on anecdotal information  
 
• Issues with developing and conducting AAT research include:  
• Gaining access to clinical settings  
• Timely IRB and IACUC approval  
• Recruiting large study samples 
• Multiple settings 
• Employing appropriate study instrumentation  
• Lack of standardized AAT protocols 
 
• Lack of research on the effects of AAT on therapy dogs 
 
www.americanhumane.org 







Designing a Study to Address the Main Findings 
Main Findings 
• Pediatric cancer patients and parents 
experience substantial distress 
• Acute lymphoblastic leukemia (ALL) is the 
most common form of childhood cancer 
• Very little rigorous research to 
quantitatively measure the efficacy of AAT 
• Very little research addressing the impact 




• Distress as the target for the AAT protocol 
 
• Population identified as ALL patients 
 
• Study design based on standard clinical 
efficacy studies   
 
• Measure impact on the therapy dogs to 




Children: Pediatric Acute Lymphoblastic Leukemia (ALL)  
H1: Pediatric cancer patients with ALL who receive AAT will 
experience less distress throughout the course of their 
treatment sessions than patients who do not receive AAT.  
Parents/Primary Caregivers 
H2: Parents/primary caregivers of pediatric cancer patients 
with ALL who receive AAT will experience less distress 
throughout the course of their child’s treatment sessions 
than parents of patients who do not receive AAT. 
Therapy Dogs 
H3: Participating therapy dogs will exhibit minimal distress 
over the course of the CCC study.  
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Study Design Overview  
• Randomized controlled clinical study 
• Control cohort receives standard-of-care 
• Study cohort receives standard-of-care plus AAT 
• Multi-site 
• Staggered start dates 
• Relatively large sample size 
• Goal is at least 100 participants 
• Validated psychosocial and biological 
instrumentation 
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Piloting the Study Design 
• Address the feasibility of conducting  a 
randomized control trial utilizing AAT 
within a pediatric healthcare setting 
 
• Determine how to address issues of 
scientific integrity and protocol fidelity 
 
• Develop recommendations for revisions to 
the protocol leading up to a final research 





• East Tennessee Children’s Hospital in 
Knoxville, TN 
• In conjunction with University of TN 
College of Veterinary Medicine 
• Monroe Carell Jr. Children’s Hospital 
at Vanderbilt in Nashville, TN 




Overview of Study Implementation Steps 
• Identify child and determine eligibility 
 
• Approach family and perform consent 
process 
 
• Receive group assignment and identifier 
 
• Determine session schedule 
 
• Match child to dog (if in treatment cohort) 
 
• Inform family 
 
• First session occurs 
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AAT Protocol for the Pilot 
• Participating child in the treatment group is matched 
with an animal-handler team 
• Visits occur approximately once a week when they come 
in for their treatment  
• Interaction with therapy team is 20 minutes, +/- 10 
minutes 
• Full data collection occurs weekly during the child’s 
induction treatment phase, then once every two months 
• Activities during session with the therapy dog are what 




Observational Scale of Behavioral Distress 




• Blood pressure taken prior to the dog 
entering the treatment session  
• Then again just prior to the dog exiting the 
treatment session 




Heart Rate Variability 
• A Polar Heart Rate Monitor is used 
during the scheduled sessions 
 
• The child wears the chest strap 
 
• The watch and chest strap are removed 
when the dog leaves the session 
 





• Collected at the time of, or shortly 
after, randomization and ID 
assignment  
 
Heart Rate Variability 




Pediatric Inventory for Parents 
• Administered at any time during or immediately after 
the session 
 
• Contains a list of 42 difficult events which parents of 
children who have a serious illness sometimes face 
 
• Parents circle HOW OFTEN the event has occurred for 
them in the past 7 days and rate how DIFFICULT the 





State Trait Anxiety Inventory 
• Administered at any time during or 
immediately after the session 
 
• Contains 20 statements for the 
caregiver to indicate how they are 
feeling at that moment on a scale 








• Completed at the conclusion of each 
session 
• Handler indicates their perception of 
their dog’s stress level 
• Note what activities took place and 
duration of the session 
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Therapy Dog Instrumentation 
Saliva 
• Salivary cortisol used as a measure of stress 
response 
• Saliva collected 20 minutes after the session 
begins 
• Compared to a baseline measure 
• Shipped to Salimetrics for analysis 
 
Ethogram 
• Video observation and coding of the dog’s 
behavior by American Humane Association  
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Next Steps for the Study 
• Continue collecting pilot data through the 
end of June 2013 
 
• Analyze pilot study data and generate 
report 
 
• Recruit 5 or more full clinical trial sites 
 
• Optimize instrumentation and protocol 
 
• Complete IRB and IACUC processes 
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